Skip to main content

Fibrosis

3
Pipeline Programs
8
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Nitto BioPharma
Nitto BioPharmaCA - San Diego
1 program
1
ND-L02-s0201Phase 1
Redx Pharma
Redx PharmaUK - Macclesfield
1 program
1
RXC007Phase 11 trial
Active Trials
NCT04931147Completed90Est. Mar 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Triamcinolone acetonidePhase 1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
HIV Accelerated Liver Disease in UgandaN/A1 trial
Active Trials
NCT01524562Completed786Est. Dec 2019
Bristol Myers Squibb
1 program
ND-L02-s0201PHASE_12 trials
Active Trials
NCT03241264Completed12Est. Oct 2016
NCT01858935Completed56Est. Feb 2014
Liminal BioSciences
1 program
PBI-4050/ PlaceboPHASE_11 trial
Active Trials
NCT04695041Completed65Est. Oct 2021
Debiopharm
DebiopharmSwitzerland - Lausanne
1 program
EPI-hNE4PHASE_21 trial
Active Trials
NCT00455767Completed84Est. Sep 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
DebiopharmEPI-hNE4
Redx PharmaRXC007
Liminal BioSciencesPBI-4050/ Placebo
Bristol Myers SquibbND-L02-s0201
Bristol Myers SquibbND-L02-s0201
Allergy TherapeuticsHIV Accelerated Liver Disease in Uganda

Clinical Trials (6)

Total enrollment: 1,093 patients across 6 trials

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

Start: Jul 2006Est. completion: Sep 200784 patients
Phase 2Completed

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Start: May 2021Est. completion: Mar 202390 patients
Phase 1Completed

A Healthy Volunteer Study of PBI-4050

Start: Dec 2020Est. completion: Oct 202165 patients
Phase 1Completed

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Start: Aug 2016Est. completion: Oct 201612 patients
Phase 1Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Start: May 2013Est. completion: Feb 201456 patients
Phase 1Completed
NCT01524562Allergy TherapeuticsHIV Accelerated Liver Disease in Uganda

HIV Accelerated Liver Disease in Uganda

Start: Dec 2011Est. completion: Dec 2019786 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.